SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Meijer JM, Meiners PM, Huddleston Slater JJ, Spijkervet FK, Kallenberg CGM, Vissink A, et al. Health-related quality of life, employment and disability in patients with Sjögren's syndrome. Rheumatology (Oxford) 2009; 48: 107782.
  • 2
    Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S, et al. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 2007; 57: 3107.
  • 3
    Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, et al. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum 2005; 52: 274050.
  • 4
    Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American—European Consensus Group. Ann Rheum Dis 2002; 61: 5548.
  • 5
    Pijpe J, Kalk WW, van der Wal JE, Vissink A, Kluin PM, Roodenburg JL, et al. Parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sjögren's syndrome. Rheumatology (Oxford) 2007; 46: 33541.
  • 6
    Dawes C. Circadian rhythms in human salivary flow rate and composition. J Physiol 1972; 220: 52945.
  • 7
    Ferguson DB, Fort A, Elliott AL, Potts AJ. Circadian rhythms in human parotid saliva flow rate and composition. Arch Oral Biol 1973; 18: 115573.
  • 8
    Burlage FR, Pijpe J, Coppes RP, Hemels ME, Meertens H, Canrinus A, et al. Variability of flow rate when collecting stimulated human parotid saliva. Eur J of Oral Sci 2005; 113: 38690.
  • 9
    Kalk WW, Vissink A, Stegenga B, Bootsma H, Nieuw Amerongen AV, Kallenberg CG. Sialometry and sialochemistry: a non-invasive approach for diagnosing Sjögren's syndrome. Ann Rheum Dis 2002; 61: 13744.
  • 10
    Kalk WW, Vissink A, Spijkervet FK, Bootsma H, Kallenberg CG, Nieuw Amerongen AV. Sialometry and sialochemistry: diagnostic tools for Sjögren's syndrome. Ann Rheum Dis 2001; 60: 11106.
  • 11
    Kalk WW, Mansour K, Vissink A, Spijkervet FK, Bootsma H, Kallenberg CG, et al. Oral and ocular manifestations in Sjögren's syndrome. J Rheumatol 2002; 29: 92430.
  • 12
    Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI): psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995; 39: 31525.
  • 13
    Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 47383.
  • 14
    Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793806.
  • 15
    Mease PJ, Revicki DA, Szechinski J, Greenwald M, Kivitz A, Barile-Fabris L, et al, for the International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) trial. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: results of the dose-ranging assessment. J Rheumatol 2008; 35: 2030.
  • 16
    Popa C, Leandro MJ, Cambridge G, Edwards JC. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford) 2007; 46: 62630.
  • 17
    Gottenberg JE, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005; 64: 91320.
  • 18
    Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J, et al. Reduction of fatigue in Sjögren's syndrome with rituximab: results of a randomised, double-blind, placebo controlled pilot study. Ann Rheum Dis 2008; 67: 15414.
  • 19
    Miyawaki S, Nishiyama S, Matoba K. Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjögren's syndrome. Intern Med 1999; 38: 93843.
  • 20
    Fox PC, Datiles M, Atkinson JC, Macynski AA, Scott J, Fletcher D, et al. Prednisone and piroxicam for treatment of primary Sjögren's syndrome. Clin Exp Rheumatol 1993; 11: 14956.
  • 21
    Pijpe J, Kalk WW, Bootsma H, Spijkervet FK, Kallenberg CG, Vissink A. Progression of salivary gland dysfunction in patients with Sjögren's syndrome. Ann Rheum Dis 2007; 66: 10712.
  • 22
    Fleischmann RM. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab. Semin Arthritis Rheum 2009; 38: 26580.
  • 23
    Gurcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 2009; 9: 1025.
  • 24
    Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007; 56: 3896908.
  • 25
    Meijer JM, Pijpe J, Bootsma H, Vissink A, Kallenberg CG. The future of biologic agents in the treatment of Sjögren's syndrome. Clin Rev Allergy Immunol 2007; 32: 2927.
  • 26
    Meijer JM, Pijpe J, Vissink A, Kallenberg CG, Bootsma H. Treatment of primary Sjögren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment. Ann Rheum Dis 2009; 68: 2845.